As well, omapatrilat, a dual ACE and NEP inhibitor has been reported to show superior antihypertensive, antiatherosclerotic, insulin‐sensitizing, and cardiovascular and renoprotective effects to ACEIs in experimental animal models for diabetes.48 This evidence concerns the gene MME and diabetes mellitus.